These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 6863934)

  • 21. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study.
    Balkarowa-Ständer J; Rother U; Rauterberg EW
    J Immunol; 1981 Sep; 127(3):1089-93. PubMed ID: 7264298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transmembrane channel-formation by five complement proteins.
    Müller-Eberhard HJ
    Biochem Soc Symp; 1985; 50():235-46. PubMed ID: 2428370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components.
    Hammer CH; Abramovitz AS; Mayer MM
    J Immunol; 1976 Sep; 117(3):830-4. PubMed ID: 956655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deviated lysis: Transfer of complement lytic activity to unsensitized cells II. Generation of the activity by inulin and by antigen antibody complexes.
    Rother U; Hänsch G; Rother K
    Z Immunitatsforsch Immunobiol; 1976 Aug; 151(1):442-54. PubMed ID: 785847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteolysis of the monomeric and dimeric C5b-9 complexes of complement: alteration in the susceptibility to proteases of the C9 subunits associated with C5b-9 dimerization.
    Yamamoto K; Migita S
    J Immunol; 1981 Aug; 127(2):423-6. PubMed ID: 7019323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxidants generated by the myeloperoxidase-halide system activate the fifth component of human complement, C5.
    Vogt W; Hesse D
    Immunobiology; 1994 Dec; 192(1-2):1-9. PubMed ID: 7750983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The complex of C5b and C6: isolation, characterization, and identification of a modified form of C5b consisting of three polypeptide chains.
    Yamamoto KI; Gewurz G
    J Immunol; 1978 Jun; 120(6):2008-15. PubMed ID: 659890
    [No Abstract]   [Full Text] [Related]  

  • 31. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain.
    Brannen CL; Sodetz JM
    Mol Immunol; 2007 Feb; 44(5):960-5. PubMed ID: 16624411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex.
    Hoover DL; Berger M; Hammer CH; Meltzer MS
    J Immunol; 1985 Jul; 135(1):570-4. PubMed ID: 3998474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complement-induced ultrastructural membrane lesions: requirement for terminal components.
    Packman CH; Rosenfeld SI; Weed RI; Leddy JP
    J Immunol; 1976 Nov; 117(5 Pt.2):1883-9. PubMed ID: 993584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
    Lint TF; Behrends CL; Baker PJ; Gewurz H
    J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps.
    Ollert MW; Kadlec JV; David K; Petrella EC; Bredehorst R; Vogel CW
    J Immunol; 1994 Sep; 153(5):2213-21. PubMed ID: 8051421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
    Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
    J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The membrane attack complex of complement: relation of C7 to the metastable membrane binding site of the intermediate complex C5b-7.
    Preissner KT; Podack ER; Müller-Eberhard HJ
    J Immunol; 1985 Jul; 135(1):445-51. PubMed ID: 3998468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
    Rollins SA; Sims PJ
    J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex.
    Kolb WP; Muller-Eberhard HJ
    J Exp Med; 1975 Apr; 141(4):724-35. PubMed ID: 47885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.